Related references
Note: Only part of the references are listed.Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
Michiro Susa et al.
BMC CANCER (2009)
Reversal of drug resistance in ovarian cancer: Where do we go from here?
Stan B. Kaye
JOURNAL OF CLINICAL ONCOLOGY (2008)
Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery
Lilian E. van Vlerken et al.
PHARMACEUTICAL RESEARCH (2007)
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group
Cindy L. Schwartz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery
M. Golzio et al.
GENE THERAPY (2007)
Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein J
Magda Lourda et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Nonfouling characteristics of dextran-containing surfaces
Surangkhana Martwiset et al.
LANGMUIR (2006)
Chemotherapy resistance in osteosarcoma: current challenges and future directions
Alexander J. Chou et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Exploiting the enhanced permeability and retention effect for tumor targeting
Arun K. Iyer et al.
DRUG DISCOVERY TODAY (2006)
Enhanced anti proliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention
Sanjeeb K. Sahoo et al.
MOLECULAR PHARMACEUTICS (2005)
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621
JE Kolitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications
H Maeda et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
PEGylated nanoparticles for biological and pharmaceutical applications
H Otsuka et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914)
P Sonneveld et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
